GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Emergent BioSolutions Inc (STU:ER4) » Definitions » Market Cap

Emergent BioSolutions (STU:ER4) Market Cap : €231 Mil (As of May. 26, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Emergent BioSolutions Market Cap?

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Emergent BioSolutions's share price for the quarter that ended in Mar. 2024 was €2.358. Emergent BioSolutions's Shares Outstanding (EOP) for the quarter that ended in Mar. 2024 was 52 Mil. Therefore, Emergent BioSolutions's market cap for the quarter that ended in Mar. 2024 was €124 Mil.

Emergent BioSolutions's quarterly market cap declined from Sep. 2023 (€160 Mil) to Dec. 2023 (€115 Mil) but then increased from Dec. 2023 (€115 Mil) to Mar. 2024 (€124 Mil).

Emergent BioSolutions's annual market cap declined from Dec. 2021 (€2,038 Mil) to Dec. 2022 (€545 Mil) and declined from Dec. 2022 (€545 Mil) to Dec. 2023 (€115 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Emergent BioSolutions's Enterprise Value for Today is €996 Mil.


Emergent BioSolutions Market Cap Historical Data

The historical data trend for Emergent BioSolutions's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Emergent BioSolutions Market Cap Chart

Emergent BioSolutions Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Market Cap
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 4,248.00 2,037.64 544.69 114.63

Emergent BioSolutions Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Market Cap Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 475.57 357.42 159.75 114.63 123.56

Competitive Comparison of Emergent BioSolutions's Market Cap

For the Drug Manufacturers - Specialty & Generic subindustry, Emergent BioSolutions's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Emergent BioSolutions's Market Cap Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Emergent BioSolutions's Market Cap distribution charts can be found below:

* The bar in red indicates where Emergent BioSolutions's Market Cap falls into.



Emergent BioSolutions Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Emergent BioSolutions's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as

Market Cap (A: Dec. 2023 )=Share Price (A: Dec. 2023 )*Shares Outstanding (EOP) (A: Dec. 2023 )
=€2.196*52.2
=€115

Emergent BioSolutions's Market Cap for the quarter that ended in Mar. 2024 is calculated as

Market Cap (Q: Mar. 2024 )=Share Price (Q: Mar. 2024 )*Shares Outstanding (EOP) (Q: Mar. 2024 )
=€2.358*52.4
=€124

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Emergent BioSolutions  (STU:ER4) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the company’s debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.


Emergent BioSolutions Market Cap Related Terms

Thank you for viewing the detailed overview of Emergent BioSolutions's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.


Emergent BioSolutions (STU:ER4) Business Description

Traded in Other Exchanges
Address
400 Professional Drive, Suite 400, Gaithersburg, MD, USA, 20879
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. The company has four main units: vaccines, which produces specialty vaccines for public health threats; devices, such as nasal sprays, skin lotions, and injections; therapeutics, which includes antibody-based treatments; and contract development and manufacturing, which brings treatments to market through collaboration with the pharmaceutical and biotechnology industries and the United States government. Most revenue comes from U.S. government purchases of vaccines, devices, and therapeutic products. The company operates in two reportable segments; the Products Segment and the Services Segment.

Emergent BioSolutions (STU:ER4) Headlines

No Headlines